KLRA · NASDAQ
Kailera Therapeutics (KLRA) Stock Price & Fundamentals
Kailera Therapeutics (KLRA) closed at $380.66 on Oct 9, 2026, up 0.13% from the previous close of $380.15.
Share price, past year
1Y +23.47%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $380.66 |
| Sep 30, 2026 | $382.23 |
| Aug 31, 2026 | $377.36 |
| Jul 31, 2026 | $342.48 |
| Jun 30, 2026 | $346.82 |
| May 29, 2026 | $354.97 |
| Apr 30, 2026 | $362.84 |
| Mar 31, 2026 | $336.98 |
| Feb 27, 2026 | $318.55 |
| Jan 30, 2026 | $309.14 |
| Dec 31, 2025 | $312.85 |
| Nov 28, 2025 | $322.27 |
| Oct 31, 2025 | $327.45 |
Key statistics
- 52-week range
- $300.24 – $384.05
Financials
Kailera Therapeutics's SEC filings don't report revenue in the standard form Laurel reads, so its revenue history isn't shown yet.
Company profile
- Name
- Kailera Therapeutics, Inc.
- Ticker
- KLRA
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 180 Third Avenue, 4th Floor, Waltham, MA 02451
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0002096997
Recent SEC filings
- Aug 12, 2026
- Aug 12, 2026
- May 26, 2026
- May 26, 2026
- Apr 20, 2026
Frequently asked questions
What is Kailera Therapeutics's stock price?
Kailera Therapeutics (KLRA) closed at $380.66 on Oct 9, 2026, up 0.13% from the previous close of $380.15.
Sources and methodology
Fundamentals come from Kailera Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures